Alpha Teknova Business Summary

Alpha Teknova, Inc. (TKNO) operates as a specialized manufacturer of critical reagents, generating revenue through the transaction-based sale of custom and catalog chemical formulations to approximately 3,000 global customers. The company's business is divided into two primary segments: Lab Essentials, which provides research-grade reagents like agar plates and microbial culture media for bench-scale discovery, and Clinical Solutions, which delivers high-purity, GMP-compliant buffers and reagents for clinical-stage and commercial bioprocessing. Teknova differentiates itself in the life sciences tools market through its modular manufacturing platform, which enables rapid turnaround of custom formulations and seamless scalability from Research Use Only (RUO) to Good Manufacturing Practice (GMP) standards. It competes directly with larger diversified players such as Cytiva, Abcam, and GenScript, positioning itself as a more agile, high-touch partner for cell and gene therapy, mRNA, and molecular diagnostics developers requiring bespoke reagent solutions. Founded in 1996 by Ted Davis, the company is currently led by President and CEO Stephen Gunstream, who previously served as Vice President and General Manager of BD Biosciences and Chief Commercial Officer at Integrated DNA Technologies (IDT). Gunstream, a named inventor on over 10 patents, holds an MBA from Duke University and a biomedical engineering degree from Northwestern. He is supported by CFO Matthew Lowell, whose pedigree includes executive finance roles at Varex Imaging and Varian Medical Systems, as well as an investment banking background at Credit Suisse First Boston and Donaldson, Lufkin & Jenrette. The company's strategic direction is overseen by a board chaired by Dr. Paul Grossman and includes notable representation from institutional backers such as Telegraph Hill Partners, with additional significant positions held by Point72 Asset Management and Jane Street Group.